Bandaríkin - enska - NLM (National Library of Medicine)

rockwell medical, inc - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). triferic is not intended for use in patients receiving peritoneal dialysis. triferic has not been studied in patients receiving home hemodialysis. none risk summary there are no data on triferic use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. in pregnant rats and rabbits, ferric pyrophosphate citrate caused adverse developmental outcomes at maternally toxic dose levels that were higher than the maximum theoretical amount of iron transferred to patients from triferic. use triferic during pregnancy only if the potential benefit justifies the potential risk to the fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background of birth defect, loss, or other adverse outcomes. in the us. general populati

Bandaríkin - enska - NLM (National Library of Medicine)

wellspring pharmaceutical corporation - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y), lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - first aid to help prevent skin infection, and for temporary relief of pain and itching associated with minor: - cuts - scrapes - burns

Bandaríkin - enska - NLM (National Library of Medicine)

wellspring pharmaceutical corporation - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y), lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - first aid to help prevent bacterial contamination or skin infection, and for temporary relief of pain and itching associated with minor: - cuts - scrapes - minor burns - sunburn - minor skin irritations

Bandaríkin - enska - NLM (National Library of Medicine)

rockwell medical inc. - ferric pyrophosphate citrate (unii: uby79oco9g) (ferric cation - unii:91o4lml611) - triferic avnu is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (hdd-ckd). limitations of use - triferic avnu is not intended for use in patients receiving peritoneal dialysis. - triferic avnu  has not been studied in patients receiving home hemodialysis. none risk summary there are no available data on triferic avnu usein pregnant women to inform a drug-associated risk of major birth defects,  miscarriage or adverse maternal or fetal outcomes. in animal reproduction studies, intravenous administration of ferric pyrophosphate citrate to pregnant rats and rabbits during organogenesis caused adverse developmental outcomes at maternally toxic dose levels that were higher than the maximum theoretical amount of iron transferred to patients from triferic avnu (see data) .  the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregna

Bandaríkin - enska - NLM (National Library of Medicine)

wellspring pharmaceutical corporation - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - first aid antiseptic first aid to help prevent bacterial contamination or skin infection in minor cuts, scrapes and burns.

Bandaríkin - enska - NLM (National Library of Medicine)

wellspring pharmaceutical corporation - benzalkonium chloride (unii: f5um2km3w7) (benzalkonium - unii:7n6jud5x6y) - active ingredients                  purpose benzalkonium                           first aid chloride 0.13%                         antiseptic first aid to help prevent bacterial contamination or skin infection in minor cuts, scrapes and burns.

Bandaríkin - enska - NLM (National Library of Medicine)

wellstat therapeutics corporation - uridine triacetate (unii: 2wp61f175m) (uridine - unii:whi7hq7h85) - uridine triacetate 951 mg in 1 g - xuriden® is indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. none risk summary there are no available data on xuriden use in pregnant women to inform a drug-associated risk. when administered orally to pregnant rats during the period of organogenesis, uridine triacetate at doses similar to the maximum recommended human dose (mrhd) of 120 mg/kg per day was not teratogenic and did not produce adverse effects on embryo-fetal development [see data] . the background risk of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. data animal data in an embryo-fetal development study, uridine triacetate was administered orally to pregnant rats during the period of organogenesis at doses up to 2000 mg/kg per day (about 2.7 times the maximum recommended human dose (mrhd) of 120

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

tinawells pty ltd -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

tinawells pty ltd -

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

tinawells pty ltd -